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ABSTRACT 
Headaches are the sixth leading cause of disability worldwide, and the 
third leading cause of disability amongst those aged 50 and older. Several 
headache disorders, including migraines, have been associated with nitric oxide 
production. It is widely accepted that the pain associated with headache 
disorders is due to the ability of nitric oxide to function as a vasodilator. While 
nitric oxide is a known vasodilator and has been linked to headache disorder, it is 
also produced in response to bacterial infections. Periodontal disease is the 
result of long term bacterial infections occurring in the gum line and nitric oxide is 
produced in response. Because periodontal disease incites the production of 
nitric oxide, it is biologically plausible that periodontal disease could be 
associated with headache disorders.  
To investigate the relationship between periodontal disease and headache 
disorders, bivariate and ordinal logistic regressions were employed while 
controlling for age, education, income, physical activity level, smoking status, 
body mass index, and diet. The population consisted of 1206, postmenopausal 
women from the Women’s Health Initiative.  
While our study reports no significant association between periodontal 
disease and headache disorders, our study did provide evidence of a link 
between Porphyromonas gingivalis, an important microbe in periodontal disease  
 
iv 
pathogenesis capable of inducing nitric oxide production, and migraines (Odds 
ratio = 2.252; 95% Confidence interval: 1.121 to 4.526).  
P. gingivalis presence is positively associated with migraines among older 
white women after controlling for potential confounders. Further investigation into 
measures of oral health, oral microbes, and NO in relation to headache disorders 
is warranted.
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CHAPTER 1 
INTRODUCTION 
1.1 BACKGROUND:  
According to the Global Burden of Disease Survey released in 2010, 
(GBD2010), headaches are the 6th leading cause of disability worldwide, and the 
3rd leading cause of disability amongst those aged 50 and older  (Stephen S 
Lim‡, Theo Vos, Abraham D Flaxman, Goodarz Danaei et al., 2012). These 
findings illustrate the large impact headache disorders have on individuals and 
society, consequently, as a response, many organizations and alliances were 
established (Steiner, Stovner, & Birbeck, 2013). For example, the World 
Headache Alliance (WHA), a coalition of over 40 organizations formed with the 
aim “to reduce the burden of headache disorders throughout the world via 
sharing information among headache organizations and by increasing the 
awareness and understanding of headaches as a public health concern with 
profound social and economic impact” (WHA, 2017). Acknowledgement of the 
global burden experienced from headache disorders has called for more work in 
understanding all aspects of these disorders (Steiner et al., 2013), as a better 
understanding of factors that trigger headaches can help in prevention and 
reduce related disability.   
One such study recently reported the possibility of a symbiotic relationship 
between oral commensal bacteria and humans through the salivary nitrate-nitrite-
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nitric oxide pathway that could provoke migraines (Gonzalez et al., 2016). That 
study proposed that the symbiotic relationship between commensal, oral bacteria 
and salivary enzymes helps reduce nitrates ingested to nitric oxide (NO), which 
has been implicated in the pathophysiology of most headache disorders, 
including migraines, tension type headaches, and cluster headaches (D’andrea 
et al., 1994; Gruber et al., 2010; Olesen, 2008; Sarchielli et al., 1996; 
Shimomura, Murakami, Kotani, Ikawa, & Kono, 1999). Migraine pain felt in the 
temporomandibular, facial, and maxillary areas has been attributed to vascular 
dilatation (Tietien, 2009), and NO is an effective vasodilator. Because of NO’s 
ability as a vasodilator, it is widely accepted that NO causes the pain suffered 
from migraines via the nociceptor activation resulting from the vascular dilatation 
of the dural and meningeal blood vessels (Schürk et. al., 2009). Consequently, 
nitrates, a precursor to NO, are commonly used as cardiac therapeutics (Thadani 
& Rodgers, 2006), with headaches being a common side effect of prescription 
nitrates (Bagdy, Riba, Kecskeméti, Chase, & Juhász, 2010). Furthermore, 
obstruction of nitric oxide synthases (NOS) has been shown to attenuate 
migraines without aura, tension-type headaches, and cluster headaches (Olesen, 
2010).  
The findings reported by Gonzalez and colleagues are the first 
contribution to headache etiology research suggesting oral microorganisms as 
the cause of headaches linked to NO (Gonzalez et al., 2016). The NIH funded 
OsteoPerio ancillary study of the Woman’s Health Initiative (WHI) has collected 
data on oral microbial species identified in 1,256 postmenopausal women from 
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Buffalo, New York. Data from this study will allow us to further investigate the 
effect of oral microbes on headache disorders, however I propose a different 
causal pathway than Gonzalez and colleagues. I propose that bacterial infections 
associated with periodontal disease induce an inflammatory response, 
specifically the production of NO, that contributes to the vasodilation and 
subsequent pain suffered in headache disorders.  
 Periodontal diseases are chronic inflammatory infections associated with 
gram-negative bacteria (Slade, Offenbacher, Beck, Heiss, & Pankow, 2000). 
Severe periodontal disease slowly destroys the supporting tooth structures 
consisting of the gums and bone. Clinically, periodontal disease is classified 
based on the degree to which the supporting tooth structures are damaged. In 
addition to being a vasodilator, NO is also an oxidant and is produced by the 
immune system in response to bacterial infections (Mancinelli & McKay, 1983). 
The lipopolysaccharides (LPS) of several gram-negative bacteria (Eun Young 
Choi et al., 2011; Kim, Ha, Choi, Choi, & Choi, 2004; Pelt, Zimmermann, Ulbrich, 
& Bernimoulin, 2002; Skaleric, Gaspirc, McCartney-Francis, Masera, & Wahl, 
2006; Hussain, Mckay, Gonzales-Marin, & Allaker, 2015; E. Y. Choi et al., 2007; 
Herath et al., 2016; Kato, Mikami, & Saito, 2001; Velsko et al., 2015; Chukkapalli 
et al., 2015) and the lipoteichoic acids of a gram-positive bacteria associated with 
periodontal disease have been shown, in vivo, to stimulate NO production by the 
immune system (English, Patrick, Orlicek, McCordic, & Shenep, 1996; Jian Jun 
Gao, Xue, Zuvanich, Haghi, & Morrison, 2001). Moreover, there is evidence of 
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increased NO production in inflamed, human gingival tissue (Kendall, Haase, Li, 
Xiao, & Bartold, 2000; Hirose et al. 2001).  
 While there is limited literature on the association between periodontal 
disease and headache disorders, there is plausible biological evidence 
supporting a causal link. The NO produced in response to periodontal disease 
could be triggering the pain suffered from headache disorders via vasodilation in 
the brain.    
1.2 PURPOSE & SPECIFIC AIMS: 
Aim 1: Assess the relationship between periodontal disease and headache 
disorders.  
Hypothesis 1a: Severe or moderate periodontal disease, as defined by the 
Centers for Disease Control and Prevention (CDC) and American 
Academy of Periodontology (AAP), is positively associated with headache 
disorders compared with mild or no periodontal disease.   
Hypothesis 1b: Increasing mean Clinical Attachment Level (CAL) is 
positively associated with headache disorders.  
Aim 2: Assess the relationship between NO-production inducing bacteria and 
headache disorders.  
Hypothesis 2a: Infection with bacteria in the dental plaque clinically shown 
to induce NO-production (model species: Streptococcus sanguis, 
Prevotella intermedia, Campylobacter rectus, Porphyromonas gingivalis, 
Fusobacterium nucleatum. and Tannerella forsythensis) is associated with 
headache disorders.  
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Hypothesis 2b: Infection with bacteria in the dental plague not clinically 
shown to induce NO-production (model species: Capnocytophaga spp., 
and Eubacterium saburreum) is not associated with headaches.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 SEARCH METHODS:  
 A literature search was conducted via PubMed to locate studies evaluating 
the association between periodontal disease and headache disorders. Advanced 
search criteria limited the search results to studies published in the English 
language and performed on human subjects. No limits were set for publication 
date. I included the following search terms: (“headache” OR “migraine” OR 
“headache disorder” OR “migraine disorder” OR “cluster headache” OR “tension-
type headache”) AND ("periodontal disease” OR "gingival disease” OR "gum 
disease” OR “periodontal disease" OR "gingivitis"). The PubMed search 
produced 28 articles and one additional article identified later, whose titles and 
abstracts were reviewed. Of those, six articles were read in their entirety to 
screen for inclusion. To be eligible for inclusion, the study had to assess the 
relationship between periodontal disease and any headache disorder. Because 
of the limited literature on this association, I also included pertinent case studies. 
Only one article assessed the relationship between periodontal disease and a 
headache disorder in an epidemiological study. Figure 2.1 is a flowchart of the 
literature review search.  
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2.2 FINDINGS:  
Two studies (Table 2.1) were included in the literature review; one was a 
case-control study (Peskersoy, Peker, Kaya, Unalp, & Gokay, 2016) and the 
other a case report (Hoffman & McCulloch, 2013). Both studies had confirmed 
cases of oral health status via a dentist administered clinical assessment.     
2.3 DISCUSSION:  
 The literature assessing the relationship between periodontal disease and 
headache disorders is extremely limited. Our literature search produced a single 
epidemiological study and one case report. Peşkersoy and colleagues recently 
published the results of their multi-center, parallel, case-controlled clinical study 
assessing the relationship between migraine disorders and oral comorbidities. 
They found that tooth wear and abrasion were more frequent in patients with 
migraines (76%, P < 0.05). Furthermore, the mean number of decayed, missing 
or filled teeth (DMFT) (mean 3.79 vs. 2.71, P < 0.05) and gingival plaque index 
scores (mean 1.64 vs. 1.23, P < 0.05) showed significant differences between 
those with and without migraines (Peskersoy et al., 2016).  However, they 
proposed that the oral comorbidities were the result of their migraine disorder 
and not vice versa, yet this case-controlled study did not establish temporality 
thus limiting the ability to determine causality. The study does, however, provide 
evidence of an association between oral health status and headache disorders 
that warrants further examination.  
 Furthermore, the case report found in our literature review was on a 60-
year-old man with a 7-year history of cluster headaches.  The patient sought 
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treatment from an oral surgeon for pain in the left upper second molar ipsilateral 
upon which the doctor discovered severe infection, decay, and inflammation 
while extracting the tooth. Removal of the infected tooth resulted in the 
attenuation of his cluster headaches. However, the authors propose that nerve 
involvement was the cause of the cluster headaches (Hoffman & McCulloch, 
2013). No measures or rankings of periodontal disease were reported for this 
case report.  
2.4 FUTURE DIRECTIONS:  
Future studies investigating the etiology of headache disorders should 
focus on oral comorbidities. While the literature investigating the relationship 
between periodontal disease and headache disorders is limited, the clinical 
evidence supports the biological plausibility outlined in the background. 
Therefore, my investigation into the relationship between periodontal disease and 
headache disorders would contribute to the limited existing literature.  
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Figure 2.1: Flowchart of literature review 
 Table 2.1: Epidemiological and clinical studies investigating the association between periodontal disease and 
headache disorders 
 
First author, 
year(s), place 
Study 
design and 
sample size 
Measure of 
periodontal 
disease 
Outcome 
variable(s) 
Control 
variables 
Main findings 
Peskersoy et 
al. 2016, 
Turkey 
Case-control, 
n=2001 
DMFT and 
gingival 
plaque index 
Migraine Adjustment was 
made for 
individual’s sex, 
age, systemic 
conditions, 
existence of 
comorbidities, 
and overall 
dental health 
and care status.  
Tooth wear and abrasion was 
more frequent in patients with 
migraine (76%, P < 0.05).  
Furthermore, the DMFT scores 
(mean 3.79 vs. 2.71, P < 0.05) 
and gingival plaque index 
scores (mean 1.64 vs. 1.23, P < 
0.05) showed significant 
differences between the groups. 
Hoffman & 
McCullough 
2013, USA 
Case report Physician 
inspection 
revealed signs 
of decay and 
periodontitis. 
No official 
diagnosis for 
periodontal 
disease was 
stated. No 
measures of 
periodontal 
disease were 
reported. 
Cluster 
headache 
N/A “A 60-year-old man with a 7-
year history of cluster 
headaches was seen by an oral 
surgeon for evaluation of pain in 
the left upper second molar 
ipsilateral to the side affected by 
the headaches. During 
extraction of the tooth, infection, 
decay, and inflammation were 
discovered. Since the extraction 
in November 2008, the patient 
has experienced one episode of 
cluster headaches as of April 
2013.”  
1
0
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CHAPTER 3 
METHODS 
3.1 STUDY POPULATION:  
Participants were recruited from the WHI OS, during their year 3 visit, to 
participate in the Buffalo Osteoporosis and Periodontal Disease Study 
(OsteoPerio Study), an ancillary study of the Women’s Health Initiative (WHI) 
Observational Study (OS) seeking to “examine the association between 
osteoporosis, oral bone loss, and periodontal disease in a well-characterized 
cohort of postmenopausal women” (Sahli et al., 2015). The OsteoPerio study has 
previously been reviewed and approved by the Health Sciences Institutional 
Review Board at the University at Buffalo, and all participants provided signed 
informed consent. Participants were offered an incentive of a free bone density 
scan and an oral examination (Brennan et al., 2007). Procedures for study 
recruitment, retention, and data collection have been previously described 
(Wactawski-Wende et al., 2005; Brennan et al., 2007; Sahli et al., 2015). My 
study population is comprised of 1,206 female participants; the population was 
reduced from 1,256, as participants with missing values for all exposures and 
outcomes of interest were excluded.  
3.2 EXPOSURE OF INTEREST FOR AIM I: 
Participants were offered free oral exams as incentive for participation in 
the OsteoPerio ancillary study. This occurred during their year three clinical 
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assessment. This included assessing the presence of decaying or filled teeth and 
accounting for each missing tooth via self-report and several measures of 
periodontal disease were taken. Moreover, samples of subgingival plaque were 
taken from each participant (Brennan et al., 2007). Pocket depth (PD) and mean 
Clinical Attachment Level (CAL) were two of the measures used to classify 
participants’ severity of periodontal disease. PD is a measure of the distance 
from the gingival margin to the bottom of the pocket and is a useful measure of 
periodontal disease. Similarly, CAL is a measure of the distance from the 
cement-enamel junction to the bottom of the pocket (American Academy of 
Periodontology, 2015). 
To address the first hypothesis of Aim 1, participants were classified as 
having no or mild, moderate, or severe periodontal disease based on the CDC 
and AAP rankings (Page & Eke, 2007), and recorded as 0, 1, or 2, respectively. 
Mild periodontal disease was defined as have two or more interdental sites with 
pocket depth (PD) ≥ 4 mm and two or more interdental sites with CAL ≥ 3 mm or 
having PD ≥ 5 mm on any tooth.  Moderate periodontal disease was defined as 
having two or more interdental sites on different teeth with CAL ≥ 4 mm or having 
PD ≥ 5 mm on more than one interdental site on different teeth. Severe 
periodontal disease was classified as having one or more interdental sites with 
PD ≥ 5 mm and two or more interdental sites with CAL ≥ 6 mm (Page & Eke, 
2007).  
Additionally, information gathered from the oral examination was used 
calculate a mean CAL for each participant. To make comparisons between 
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various levels of mean CAL, participants were divided into four groups, the 
quartiles of mean CAL. Quartile 1 (Q1) is comprised of participants with a mean 
CAL less than or equal to 1.95. Quartile 2 (Q2) is comprised of participants with a 
mean CAL greater than 1.95 and less than or equal to 2.27. Quartile 3 (Q3) is 
comprised of participants with a mean CAL greater than 2.27 and less than or 
equal to 2.66. Lastly, Quartile 4 (Q4) is comprised of participants with a mean 
CAL greater than 2.66. Additionally, mean CAL was divided into quartiles within 
all logistic regression models.  
3.3 EXPOSURE OF INTEREST FOR AIM II: 
 As part of the oral examination received by participants in OsteoPerio 
ancillary study, subgingival plaque samples were taken via the paper point 
technique (Brennan et al., 2007). Samples were taken from up to 12 teeth 
previously dried with cotton to reduce contamination. The following species were 
selected for this study and detected via immunofluorescence: Streptococcus 
sanguis, Prevotella intermedia, Campylobacter rectus, Porphyromonas gingivalis, 
Fusobacterium nucleatum. Tannerella forsythensis, Capnocytophaga spp., and 
Eubacterium saburreum. Methods have been previously described in detail 
(Brennan et al., 2007).  
 For this study, the bacterial species were divided into two groups. A 
literature search was conducted for clinical evidence of inducing NO production 
for each of the targeted bacterial species. Results from the search are recorded 
in Table 3.1. Group 1 consists of bacterial species that may induce NO 
production, as supported by literature, and Group 2 consists of the remaining 
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bacterial species not known to induce NO production. Group 1 includes S. 
sanguis, P. intermedia, C. rectus, P. gingivalis, F. nucleatum, and T. forsythensis. 
Group 2 includes the remaining species as there is no literature reporting the 
ability of Capnocytophaga spp. or E. saburreum to induce NO production. All 
species were recoded as either present (1) or absent (0); therefore, an additional 
variable “Infection” was created to illustrate the number of Group 1 bacteria 
identified in each participant. All participants who were infected with two or less 
Group 1 bacteria were considered to have no or mild infection. Participants who 
were infected with three or four Group 1 bacteria were considered to have 
moderate infection; and participants who were infected with five or six Group 1 
bacteria were considered to have severe infection.  
3.4 OUTCOMES OF INTEREST:  
3.4.1 Migraines 
During their baseline visit for the WHI OS, participants were asked “Has a 
doctor told you that you have any of the following conditions or have you had any 
of the following procedures?” and were provided a list that included migraine 
headaches. Participants responses were coded as absent (0) or present (1). 
Because the presence of migraines was recorded as absent or present, with no 
information about type of migraine, bivariate logistic regression was used for all 
models assessing the relationship between migraines and our exposures of 
interest.  
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3.4.2 Headaches 
During their third-year visit, participants were given a list of symptoms, one 
of which being headaches or migraines, and asked “for each item, mark the 
one… [response] that best describes how bothersome the symptom was during 
the past 4 weeks for you”. The options were “Symptom did not occur”, “Symptom 
was mild” defined as symptom did not interfere with usual activities, “Symptom 
was moderate” defined as symptom interfered somewhat with usual activities, or 
“Symptom was severe” defined as symptom was so bothersome that usual 
activities could not be performed. The response to this question was used as an 
indicator of the presence of any headache disorder, and because the response 
was recorded ordinally, ordinal or cumulative logistic regression was 
implemented in all models examining the relationship between our exposures of 
interest and headache disorders.  
3.5 POTENTIAL CONFOUNDERS: 
The following variables were identified as potential confounders via a 
literature search: age, education, income, race, body mass index (BMI), anxiety, 
depression, smoking, physical activity, cholesterol, medication use, blood 
pressure, and eating behaviors (Aamodt, Stovner, Midthjell, Hagen, & Zwart, 
2007; Bond, Roth, Nash, & Wing, 2011; Buse, Silberstein, Manack, 
Papapetropoulos, & Lipton, 2013; Cappy, Lucas, Catteau-Jonard, & Robin, 2015; 
Fagernæs et al., 2015; Heckman & Britton, 2015; Martin & Vij, 2016; Stovner et 
al., 2007; Thadani & Rodgers, 2006; Varkey, Hagen, Zwart, & Linde, 2008; 
Younger, 2016). However, data collected on cholesterol were too incomplete to 
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include in the analysis and the population was mostly white (97.4%) thus race 
was also excluded from the analysis. The remaining potential confounders were 
controlled for in each model to create the most theoretically based model. Refer 
to Figure 3.1, a Directed Acyclic Graph (DAG) illustrating the association 
between periodontal disease and headache disorders and the previously 
mentioned potential confounders. Additionally, Table 3.2 lists each variable 
treated as a potential confounder when building the model, literature justifying 
why the variable was considered a confounder, and how the variable was 
recorded.  
3.6 STATISTICAL ANALYSIS:  
3.6.1 Demographic differences 
 Participants were ranked by periodontal disease status as defined by the 
CDC and AAP. Comparisons were made between those with no or mild 
periodontal disease versus those with moderate or severe periodontal disease. 
Differences in continuous variables are recorded as the mean and standard 
deviation (SD) and assessed via the Student t test. Categorical variables were 
assessed via the Pearson Chi-square test or the Fischer’s Exact test when 
appropriate. 
 Similarly, differences between participants at the four quartiles of mean 
CAL are recorded in Table 5. Comparisons were made between Q1, Q2, Q3, and 
Q4 of mean CAL. Differences in continuous variables are recorded as the mean 
and standard deviation (SD) and assessed via the one-way ANOVA test. 
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Categorical variables were assessed via the Pearson Chi-square test or the 
Fischer’s Exact test when appropriate. 
 Furthermore, comparisons were made between those with no or mild, 
moderate, or severe Group 1 bacterial infections. Differences in continuous 
variables are recorded as the mean and standard deviation (SD) and assessed 
via one-way ANOVA test. Categorical variables were assessed via the Pearson 
Chi-square test or the Fischer’s Exact test when appropriate. 
 Lastly, comparisons were made between the participants with no, one, or 
two Group 2 bacteria present. Differences in continuous variables are recorded 
as the mean and standard deviation (SD) and assessed via the one-way ANOVA 
test. Categorical variables were assessed via the Pearson Chi-square test or the 
Fischer’s Exact test when appropriate. 
3.6.2 Models 
3.6.2.1 Migraines 
 To address the hypotheses stated in Aim 1, periodontal disease status 
was defined two ways, by CDC/AAP rankings and by mean CAL quartiles. To 
address Hypothesis 1a, bivariate logistic regression was implemented to 
determine the odds of having suffered migraines for those with moderate or 
severe periodontal disease compared to those with no or mild periodontal 
disease while controlling for age at enrollment, history of using birth control, 
cardiac therapeutic usage, caffeine intake in mg, and alcohol servings per week. 
Furthermore, an additional bivariate logistic regression was used to determine 
the odds of having suffered migraines for those with mean CAL in quartile 2, 3, 
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and 4 compared to quartile 1 to address Hypothesis 1b. Similarly, this model also 
controlled for age at enrollment, history of using birth control, cardiac therapeutic 
usage, caffeine intake in mg, and alcohol servings per week.  
 To address both hypotheses stated in Aim 2, a final bivariate logistic 
regression model was employed to determine the odds of having suffered a 
migraine for those with moderate or severe infection of Group 1 bacteria 
compared to those with no or mild infection of Group 1 bacteria while controlling 
for the presence or absence of Group 2 bacteria, age at enrollment, history of 
using birth control, cardiac therapeutic usage, caffeine intake in mg, and alcohol 
servings per week. It is necessary to control for the presence of Group 2 bacteria 
within the model assessing the relationship between Group 1 bacteria and 
migraines; therefore, we only need the single model to address both hypotheses 
from Aim 2. Additional bivariate logistic regression models were used to assess 
the relationship between each Group 1 bacterial species and migraines. All six 
models controlled for age at enrollment, history of using birth control, cardiac 
therapeutic usage, caffeine intake in mg, and alcohol servings per week.  
3.6.2.2 Headache disorders 
 Methods for assessing the odds of having suffered a headache disorder 
for each hypothesis are like the previously mentioned methods for assessing the 
odds of having suffered a migraine, with a few exceptions. Because participants 
were asked if they had suffered no or mild, moderate, or severe pain, ordinal 
regression was employed to determine the odds of having suffered a headache 
disorder for all exposures. All models controlled for age at enrollment, history of 
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using birth control, cardiac therapeutic usage, blood pressure, and alcohol 
servings per week.
 20
 
 
 
Figure 3.1: Directed Acyclic Graph (DAG) of the association between periodontal 
disease and headache disorders 
a. Sources: Katz et al., 2002 
b. Sources: Mirowsky & Ross, 1992; Jorm, 2000; Twenge, 2000; Stevens et 
al., 1998; Franklin et al., 1997; Schaefer et al., 1994  
c. Sources: Leite et al. ,2017; Bodnar et al., 2017; Green & Benzeval,d 
2013; Wardle & Steptoe, 2003; Hagen et al., 2002; Martikainen & Marmot 
2017; Colhoun, Hemingway, & Poulter 1998; Winkleby, et al. 1998 
d. Sources: Aamodt, Stovner, Midthjell, Hagen, & Zwart, 2007; Primatesta et 
al., 2001;  Gepner et al., 2011; Tomar & Asma, 2000 
e. Sources: Varkey, Hagen, Zwart, & Linde, 2008; Stefanick et al., 1998; 
Cornelissen & Smart, 2013; WHO 2013; Bawadi et al., 2011 
f. Sources: Fagernæs et al., 2015; Prospective Studies Collaboration, 2007 
g. Sources: Bond, Roth, Nash, & Wing, 2011; Brown et al., 2000; Faheem et 
al., 2010 
h. Sources: Thadani & Rodgers, 2006; Cappy, Lucas, Catteau-Jonard, & 
Robin, 2015 
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Table 3.1 Group 1 and Group 2 bacterial species 
 
Bacteria spp. and 
characteristics 
Support 
Group 1: NO production inducting bacteria  
   Streptococcus sanguis 
 
While periodontal disease is typically associated 
with gram-negative bacteria, the lipoteichoic 
acids from S. sanguis has been shown to 
stimulate NO production from murine and 
C3H/HeJ macrophages (English, Patrick, Orlicek, 
McCordic, & Shenep, 1996; Jian Jun Gao, Xue, 
Zuvanich, Haghi, & Morrison, 2001).  
   Prevotella intermedia P. intermedia lipopolysaccharide (LPS) has been 
shown to stimulate the release of NO (Eun Young 
Choi et al., 2011; Kim, Ha, Choi, Choi, & Choi, 
2004; Pelt, Zimmermann, Ulbrich, & Bernimoulin, 
2002; Skaleric, Gaspirc, McCartney-Francis, 
Masera, & Wahl, 2006) 
   Campylobacter rectus C. rectus LPS has been shown to induce NO 
production in oral keratinocytes (Hussain, Mckay, 
Gonzales-Marin, & Allaker, 2015) 
   Porphyromonas  
   gingivalis  
P. gingivalis lipid A-associated proteins and LPS 
can induce nitric oxide production (E. Y. Choi et 
al., 2007; Herath et al., 2016). 
   Fusobacterium  
   nucleatum 
Live F. nucleatum  can induce NO production in 
murine macrophages (Kato, Mikami, & Saito, 
2001).  
   Tannerella forsythensis    
   (formally known as T.  
   forsythia) 
There is evidence that a polymicrobial consortium 
including Tannerella forsythia was shown to 
increase NO production (Velsko et al., 2015). 
However, there are conflicting reports on 
whether T. forsthensis induces NO 
production (Chukkapalli et al., 2015). 
  
Group 2: Control bacteria not considered to induce NO production 
   Capnocytophaga spp. No evidence of inducing NO production 
   Eubacterium  
   saburreum 
No evidence of inducing NO production 
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Table 3.2: Potential confounders for the association between periodontal 
disease and headache disorders 
 
Variable Justification 
   Age at baseline Will include to control for age as a potential confounder 
and to prevent any age affects.  
   Education When defining SES by educational level or type of 
occupation, low status was associated with increased 
risk of frequent and chronic headache at follow-up. 
(Hagen et al., 2002) 
   Income Previous studies found that risk of headache decreased 
with increasing income, but only among men (Hagen et 
al., 2002).  It’s still important to see how income affects 
headaches in this exclusively female population.  
   BMI Evidence indicates a possible link between migraine and 
obesity, with the latter either exacerbating headache 
activity in people currently suffering from migraine or 
possibly increasing the risk for having migraine. (Bond et 
al., 2011) 
   Depression     
   variable  
Migraine is comorbid with several psychiatric disorders, 
including depression, anxiety disorders, and PTSD. 
(Buse et al., 2013) 
   Smoking Passive smoking was associated with higher headache 
prevalence. (Aamodt et al., 2007) 
   Physical Activity A study reported that individuals reporting headaches 
were typically less active (Varkey et al., 2008). 
   Medication use:  
   Cardiac  
   therapeutics  
Nitrates are effective cardiac agents; however 
headaches are the most common consequence (Thadani 
& Rodgers, 2006). 
   Medication use:    
   Oral  
   contraceptive 
Oral contraceptives have been associated with migraine 
disorders (Cappy et al., 2015). 
   Blood pressure Two large-scale population-based cohort studies, 
HUNT2 and HUNT3 reported an inverse association 
between blood pressure and headaches (Fagernæs et 
al., 2015). 
   Dietary intake:     
   Caffeine 
Caffeine withdrawal has been reported to trigger 
headaches (Martin & Vij, 2016).  
Headaches are associated with alcohol overuse (Aamodt 
et al., 2007) (Martin & Vij, 2016). 
Caffeine withdrawal have the strongest evidence for 
triggering attacks of headache (Martin & Vij, 2016) 
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CHAPTER 4 
RESULTS 
4.1 POPULATION DEMOGRAPHICS: 
Population characteristics are shown in Tables 4.1-10. Table 4.1 displays 
our population characteristics by each exposure level that addresses our 
hypotheses. The majority of the study population suffers from periodontal 
disease with 16.25% suffering from severe periodontal disease and 57.05% 
suffering from moderate periodontal disease. Most participants (51.49%), were 
infected with one or two Group 1 bacteria, and no Group 2 bacteria (50.58%). 
Results are shown in Table 4.  
As shown in Tables 4.2 and 4.3, differences between participants with 
moderate or severe periodontal disease were older, more likely to be former or 
current smokers, were less physically active, and were more likely to be infected 
with P. intermedia, T. forsythensis, E. saburreum, C. rectus, and P. gingivalis 
than participants with no or mild periodontal disease. No statistically significant 
differences were observed between participants with moderate or severe 
periodontal disease versus participants with no or mild periodontal disease with 
regards to BMI, history of birth control usage, cardiac therapeutic usage, diastolic 
blood pressure, caffeine intake, alcohol servings per week, and the presence of 
S. sanguis, Capnocytophaga spp. or F. nucleatum.  
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Differences between the quartiles of mean CAL are also found in Tables 
4.4-4.6. Participants in the fourth quartile are older, more likely to be current 
smokers, less physically active, and are more likely to be infected with P. 
intermedia, T. forsythensis, E. saburreum, C. rectus, and P. gingivalis. 
Additionally, participants in the third and fourth quartiles drank more caffeine than 
participants in the first and second quartiles. No significant differences were seen 
between the four quartiles in regard to total family income, education, BMI, 
history of birth control usage, cardia therapeutic usage, diastolic blood pressure, 
alcohol servings per week, or infection with S. sanguis, Capnocytophaga sp., and 
F. nucleatum.  
 As see in Tables 4.7 and 4.8, participants with severe infections of Group 
1 bacteria were more likely to be overweight, less likely to be current smokers, 
drank more caffeine, and were more likely to be about of the fourth quartile of 
Mean CAL. Similarly, participants with more severe Group 2 infections were also 
more likely to be overweight (Tables 4.9-4.10). Differences between the varying 
degrees of infections for Group 1 and Group 2 bacteria are recorded in Table 6.  
4.2 MODEL RESULTS: 
4.2.1 Migraines 
Results from crude and adjusted models assessing the specific aims and 
all hypotheses for migraines is displayed in Table 4.11. To address Aim 1, 
bivariate logistic regression models were implemented to assess the relationship 
between periodontal disease and migraines; periodontal disease was defined two 
ways, by CDC/AAP rankings and by Mean CAL. Severe or moderate periodontal 
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disease defined by CDC/AAP rankings was not associated with migraines in both 
unadjusted (OR = 0.812, 95% CI: 0.544, 1.213) and adjusted (OR = 0.811, 95% 
CI: 0.530, 1.241) models. Similarly, periodontal disease classified by quartiles of 
Mean CAL was not associated with migraines in both unadjusted and adjusted 
models when comparing the second and third quartiles to the first quartile. The 
unadjusted and adjusted OR for participants in the second quartile of Mean CAL 
was 1.109, 95% CI: 0.673, 1.827 and 1.071, 95% CI: 0.628, 1.828, respectively. 
When comparing participants in the third quartile of Mean CAL to participants in 
the first quartile of Mean CAL, the odds of suffering from a migraine were 1.746, 
95% CI: 1.000, 3.048 in the crude model and 1.638, 95% CI: 0.904, 2.966, in the 
adjusted model. However, for participants in the fourth quartile, the unadjusted 
association between Mean CAL was not associated with migraines in the crude 
(unadjusted OR = 1.065, 95% CI 0.648, 1.749) or adjusted models (adjusted OR 
= 0.930, 95% CI: 0.546, 1.584). Both adjusted models controlled for age, 
education, income, BMI, smoking status, physical activity, history of birth control, 
cardiac therapeutic usage, diastolic blood pressure, alcohol consumption, and 
caffeine consumption. 
To address hypotheses from Aim 2, a bivariate logistic regression model 
was implemented to assess the relationship between Group 1 and 2 bacteria and 
migraines. The adjusted model controlled for all the above-mentioned covariates. 
The relationship between Group 1 bacterial species and migraines was assessed 
two ways, via an infection ranking and by assessing the relationship between the 
presence of each individual bacterial species. More information on the bacterial 
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species of interest and the infection ranking is in section 3.3. Moderate and 
severe infection with Group 1 bacteria approached positive associations with 
migraines in unadjusted and adjusted models, but did not reach statistical 
significance. Participants with moderate infection compared to those with no or 
mild infection had an unadjusted OR of 1.622, 95% CI: 0.992, 2.652 and adjusted 
OR 1.511, 95% CI: 0.879, 2.599. Also, participants with severe infection 
compared to those with no or mild infection have unadjusted OR 1.589, 95% CI: 
0.673, 3.754 and adjusted OR 1.293, 95% CI: 0.508, 3.288. The presence of P. 
gingivalis was positively associated with migraines in unadjusted (OR = 2.109, 
95% CI: 1.082, 4.110), and adjusted (OR = 2.252, 95% CI: 1.121, 4.526) models. 
Other individual Group 1 bacterial species were not associated with migraines.  
Infection with one or two Group 2 bacteria, the control bacteria, were not 
associated with migraines. The odds of suffering from migraines for those with a 
single infection of Group 2 bacteria was 0.821, 95% CI: 0.545, 1.236 in the 
unadjusted model and 0.776, 95% CI: 0.498, 1.207 in the adjusted model. 
Infection with two Group 2 bacteria resulted in an unadjusted OR of 1.455, 95% 
CI: 0.852, 2.484 and adjusted OR of 1.363, 95% CI: 0.756, 2.458. Both Group 2 
bacterial species, Capnocytophaga sp. and E. saburreum, were positively, yet 
insignificantly associated with migraines in crude and adjusted analyses.  
4.2.2 Headaches 
Similar analyses were performed to also assess the relationship between 
our exposures and headache disorders; however, the variable for headache 
disorders was recorded as an ordinal variable with four options. As such, ordinal 
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logistic regression was implemented and results for all crude and adjusted 
models related to headache disorders were recorded in Tables 4.12-4.14.  The 
odds of suffering from mild, moderate, and severe headache symptoms are 
recorded in Tables 4.12, 4.13, and 4.14, respectively. From these data, we must 
conclude that periodontal disease was not associated with headaches. Severe or 
moderate periodontal disease as defined by the CDC/AAP rankings was not 
significantly associated with any level of headache pain. For participants 
suffering from moderate or severe periodontal disease, the odds of suffering mild 
headache symptoms were 0.865, 95% CI: 0.699, 1.119 in the crude model and 
0.758, 95% CI: 0.336,1.667 in the adjusted model. For participants suffering from 
moderate or severe periodontal disease the odds of suffering from moderate 
headache symptoms was 0.737, 95% CI: 0.497,1.091 in the crude model and 
0.728, 95% CI: 0.483,1.098 in the adjusted model. For participants suffering from 
moderate or severe periodontal disease the odds of suffering from severe 
headache symptoms was 0.768, 95% CI: 0.358,1.650 in the unadjusted model 
and 0.758, 95% CI: 0.336, 1.710 in the adjusted model. The adjusted model 
controlled for age, education, income, BMI, smoking status, physical activity, 
history of birth control, cardiac therapeutic usage, diastolic blood pressure, 
alcohol consumption, and caffeine consumption. 
To address Hypothesis 2 from Aim 1, ordinal logistic regression was 
implemented to assess the relationship between mean CAL and suffering various 
levels of headache pain. Again, our data suggests no relationship between 
periodontal disease and headaches. For participants in the second quartile of 
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Mean CAL, the odds of suffering from mild headache symptoms was 1.015, 95% 
CI: 0.735, 1.402 in the unadjusted model and 0.986, 95% CI: 0.701,1.387 in the 
adjusted model.  For participants in the third quartile of Mean CAL, the odds of 
suffering from moderate headache symptoms was 0.699, 95% CI: 0.402,1.112 in 
the unadjusted model and 0.614, 95% CI: 0.356,1.059 in the adjusted model. 
Lastly, for participants in the fourth quartile of Mean CAL, the odds of suffering 
from severe headache symptoms was 0.518, 95% CI: 0.189,1.419 in the 
unadjusted model and 0.510, 95% CI: 0.168,1.544 in the adjusted model. The 
adjusted model controlled for age, education, income, BMI, smoking status, 
physical activity, history of birth control, cardiac therapeutic usage, diastolic blood 
pressure, alcohol consumption, and caffeine consumption. 
To address both hypotheses from Aim 2, ordinal logistic regression was 
used to assess the relationship between Group 1 and 2 bacteria and headache 
disorders. All adjusted models addressing Aim 2 controlled for age, education, 
income, BMI, smoking status, physical activity, history of birth control, cardiac 
therapeutic usage, diastolic blood pressure, alcohol consumption, and caffeine 
consumption. To address first hypothesis in Aim 2, ordinal logistic regression was 
implemented to assess the relationship between Group 1 bacteria and headache 
disorders. Moderate infection with Group 1 bacteria was not significantly 
associated with any level of headache pain. For participants with moderate 
infection of Group 1 bacteria, the odds of suffering from mild headache 
symptoms were 0.855, 95% CI: 0.649,1.125 in the unadjusted model and 0.844, 
95% CI: 0.623,1.144 in the adjusted model. For participants with moderate 
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infection of Group 1 bacteria, the odds of suffering from moderate headache 
symptoms was 0.875, 95% CI: 0.561,1.366 in the unadjusted model and 0.819, 
95% CI: 0.507,1.322 in the adjusted model. Lastly, for participants with moderate 
infection of Group 1 bacteria, the odds of suffering from severe headachy 
symptoms was 0.819, 95% CI: 0.507,1.322 in the unadjusted model and 0.726, 
95% CI: 0.269,1.956 in the adjusted model.  Similarly, severe infection with 
Group 1 bacteria was insignificantly associated with all levels of headache pain. 
For participants with severe infection of Group 1 bacteria, the odds of suffering 
from mild headache symptoms was 0.801, 95% CI: 0.499,1.287 in the 
unadjusted model and 0.855, 95% CI: 0.527,1.488 in the adjusted model. For 
participants with severe infection of Group 1 bacteria, the odds of suffering from 
moderate headache symptoms was 0.422, 95% CI: 0.151,1.181 in the 
unadjusted model and 0.458, 95% CI: 0.161,1.306 in the adjusted model. For 
participants with severe infection of Group 1 bacteria, the odds of suffering from 
severe headache symptoms was 0.431, 95% CI: 0.058,3.229 in the unadjusted 
model and 0.530, 95% CI: 0.070,4.024 in the adjusted model. None of the Group 
1 species were significantly associated with any symptoms suffered from 
headaches.  
Infection with one Group 2 bacterium was insignificantly associated with 
suffering from mild headache symptoms in the unadjusted (unadjusted OR = 
0.986, 95% CI: 0.755,1.287) and adjusted models (adjusted OR = 1.016, 95% CI: 
0.764,1.352). Conversely, infection with one Group 2 bacterium was significantly 
associated with mild headache symptoms in both the unadjusted and adjusted 
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models with OR of 1.672, 95% CI: 1.111,2.516 and 1.753, 95% CI: 1.139,2.697, 
respectively. Likewise, infection with one Group 2 bacterium was significantly 
associated with severe headache symptoms in both unadjusted and adjusted 
models with OR of 2.856, 95% CI: 1.281,6.368 and 3.169, 95% CI: 1.310,7.663, 
respectively. Infection with two Group 2 bacteria was not significantly associated 
with suffering from mild headache symptoms in the unadjusted and adjusted 
models with ORs of 0.902, 95% CI: 0.670,1.215 and 0.973, 95% CI: 0.695,1.363, 
respectively. However, infection with two Group 2 bacteria was not significantly 
associated with suffering from moderate and severe headache symptoms in 
crude and adjusted models. Infection with two Group 2 bacteria resulted in OR of 
1.051, 95% CI: 0.635,1.740 and 1.168, 95% CI: 0.683,1.998 in the crude and 
adjusted models respectively for suffering from moderate headache symptoms. 
Infection with two Group 2 bacteria resulted in OR of 1.202, 95% CI: 0.407,3.555 
and 1.578, 95% CI: 0.507,4.910 in the crude and adjusted models respectively 
for those suffering from severe headache symptoms. No individual species of 
Group 2 bacteria was significantly associated with any level of headache 
symptoms. 
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Table 4.1 Population demographics for WHI OsteoPerio ancillary study 
participants for each exposure of interest 
 
Variable Definition n (%) 
CDC/AAP Rankings of Periodontal Disease 
No or mild disease 
Two or more interdental sites with 
pocket depth (PD)4 mm and two or 
more interdental sites with CAL 3 mm 
or having PD5 mm on any tooth. 
322 (26.70) 
Moderate disease 
Two or more interdental sites on 
different teeth with CAL4 mm or 
having PD 5 mm on more than one 
interdental site on different teeth. 
688 (57.05) 
Severe disease 
One or more interdental sites with PD5 
mm and two or more interdental sites 
with CAL6 mm. 
196 (16.25) 
Mean CAL Quartiles 
Q1 Mean CAL less than or equal to 1.95 296 (24.54) 
Q2 
Mean CAL greater than 1.95 and less 
than or equal to 2.27 
304 (25.21) 
Q3 
Mean CAL greater than 2.27 and less 
than or equal to 2.66 
302 (25.04) 
Q4 Mean CAL greater than 2.66 304 (25.21) 
Group 1 Bacteria 
No disease No Group 1 bacteria 229 (18.99) 
Mild disease 1 or 2 Group 1 bacteria 621 (51.49) 
Moderate Disease 3 or 4 Group 1 bacteria 278 (23.05) 
Severe Disease 5 or 6 Group 1 bacteria  78 (6.47) 
Group 2 Bacteria 
No Group 1 
bacteria present 
No Group 2 bacteria 610 (50.58) 
1 Group 1 
bacterium present 
1 Group 2 bacteria 346 (28.69) 
2 Group 1 bacteria 
present 
2 Group 2 bacteria 250 (20.73) 
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Table 4.2. Population categorical characteristics for WHI OsteoPerio ancillary 
study participants by CDC/AAP rankings  
 
 
 
CDC/AAP Periodontal Disease 
Definition 
 
Total 
(n = 1206) 
No/Mild 
(n=322) 
Moderate/ 
Severe 
(n=884) 
P value 
Age at enrollment     
   <70 years 802 (66.50) 234 (72.67) 568 (64.25) 
0.0061 
   ≥70 years 402 (33.50) 88 (27.33) 316 (35.75) 
Total family income     
   <$50,000 756 (62.69) 186 (57.76) 570 (64.48) 
0.0329 
   ≥$50,000 450 (37.31) 136 (42.24) 314 (35.52) 
Education     
   High School 249 (21.01) 57 (17.92) 192 (22.15) 
0.2225    College 530 (44.73) 143 (44.97) 387 (44.64) 
   Post-College 406 (34.26) 118 (37.11) 288 (33.22) 
BMI     
   Underweight/ 
   Normal 
   (< 24.9 kg/m2) 
541 (44.86) 137 (42.55) 404 (45.70) 
0.6041    Overweight  
   (25.0- 29.9 kg/m2) 
411 (34.08) 113 (35.09) 298 (33.71) 
   Obese  
   (≥30.0 kg/m2) 254 (21.06) 72 (22.36) 182 (20.59) 
Cigarette smoking     
   Never 635 (52.65) 190 (59.01) 445 (50.34) 
0.0202    Former 531 (44.03) 125 (38.82) 406 (45.93) 
   Current 40 (3.32) 7 (2.17) 33 (3.73) 
Birth control usage 456 (37.81) 126 (39.13) 330 (37.33) 0.5685 
Cardiac therapeutic 
usage 
29 (2.41) 7 (2.17) 22 (2.49) 0.4564 
Bacterial sp., No. (%)     
   S. sanguis 713 (59.12) 187 (58.07) 526 (59.50) 0.6555 
   P. intermedia 515 (42.70) 119 (36.96) 396 (44.80) 0.0149 
   T. forsythensis 453 (37.65) 74 (22.98) 379 (42.87) <.0001 
   Capnocytophaga sp. 450 (37.31) 112 (34.78) 338 (38.24) <.0001 
   E. saburreum 168 (13.93) 76 (23.60) 320 (36.20) <.0001 
   C. rectus  202 (16.75) 43 (13.35) 159 (17.99) 0.0567 
   P. gingivalis 175 (14.51) 25 (7.76) 150 (16.97) <.0001 
   F. nucleatum 168 (13.93) 38 (11.80) 130 (14.71) 0.1975 
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Table 4.3. Population continuous characteristics for WHI OsteoPerio ancillary 
study participants by CDC/AAP rankings  
 
 
 
CDC/AAP Periodontal Disease 
Definition 
 
Total 
(n = 1206) 
No/Mild 
(n=322) 
Moderate/ 
Severe 
(n=884) 
P value 
Age at 
enrollment, 
mean±SD, y 
66.47±6.96 65.32±6.87 66.90±6.95 0.5743 
Physical activity, 
mean±SD, MET 
hours per week 
14.44±14.31 15.97±16.30 13.89±13.48 0.0270 
Diastolic BP, 
mean±SD, mmHg 70.78±8.96 71.03±8.95 70.70±8.96 0.5743 
Caffeine intake, 
mean±SD, dietary 
caffeine mg 
167.86±127.43 156.4±116.5 172.0±131.0 0.0662 
Alcohol intake, 
mean±SD, 
servings per week 
2.69±1.75 2.48±4.20 2.76±4.93 0.3746 
 
  
 Table 4.4. Population categorical characteristics for WHI OsteoPerio ancillary study participants by Mean CAL 
quartiles  
 
 Quartiles of Mean CAL 
 Q1 
(n=296) 
Q2 
(n=304) 
Q3 
(n=302) 
Q4 
(n=304) 
P value 
Age at enrollment      
   <70 years 200 (67.57) 211 (69.41) 207 (68.54) 184 (60.53) 
0.0806 
   ≥70 years 96 (32.43) 93 (30.59) 95 (31.46) 120 (39.47) 
Total family income      
   <$50,000 180 (60.81) 180 (59.21) 187 (61.92) 209 (68.75) 
0.0762 
   ≥$50,000 116 (39.19) 124 (40.79) 115 (38.08) 95 (31.25) 
Education      
   High School 50 (17.24) 63 (20.93) 57 (19.32) 79 (26.42) 
0.0807    College 126 (43.45) 135 (44.85) 136 (46.10) 133 (44.48) 
   Post-College 114 (39.31) 103 (34.22) 102 (34.58) 87 (29.10) 
BMI      
   Underweight/ 
   Normal (< 24.9 kg/m2) 
124 (41.89) 147 (48.36) 140 (46.36) 130 (42.76) 
0.2129    Overweight  
   (25.0- 29.9 kg/m2) 
104 (35.14) 97 (31.91) 111 (36.75) 99 (32.57) 
   Obese (≥30.0 kg/m2) 68 (22.97) 60 (19.74) 51 (16.89) 75 (24.67) 
Cigarette smoking      
   Never 178 (60.14) 182 (59.87) 139 (46.03) 136 (44.74) 
<.0001    Former 110 (37.16) 118 (38.82) 155 (51.32) 148 (48.68) 
   Current 8 (2.70) 4 (1.32) 8 (2.65) 20 (6.58) 
Birth control usage 104 (35.14) 126 (41.45) 115 (38.08) 111 (36.51) 0.4173 
Cardiac therapeutic 
usage 
10 (3.38) 5 (1.65) 5 (1.67) 9 (2.97) 0.3870 
3
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Table 4.5 Population continuous characteristics for WHI OsteoPerio ancillary study participants by Mean CAL 
quartiles 
 
 Quartiles of Mean CAL 
 Q1 
(n=296) 
Q2 
(n=304) 
Q3 
(n=302) 
Q4 
(n=304) 
P value 
Age at enrollment, 
mean±SD, y 66.20±6.83 65.91±7.03 66.06±7.10 67.72±6.75 0.0040 
Physical activity, 
mean±SD, MET hours 
per week 
16.08±17.01 13.61±12.46 15.33±14.68 12.83±12.56 0.0214 
Diastolic BP, 
mean±SD, mmHg 70.35±9.12 71.16±8.68 70.74±8.73 70.87±9.30 0.7444 
Caffeine intake, 
mean±SD, dietary 
caffeine mg 
156.02±111.26 158.46±119.46 183.29±139.53 173.25±135.47 0.0314 
Alcohol intake, 
mean±SD, servings 
per week 
2.02±3.55 2.81±4.56 3.01±5.43 2.89±5.14 0.0542 
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Table 4.6 Population microbial community characteristics for WHI OsteoPerio ancillary study participants by Mean 
CAL quartiles 
 
 Quartiles of Mean CAL 
 Q1 
(n=296) 
Q2 
(n=304) 
Q3 
(n=302) 
Q4 
(n=304) 
P value 
Bacterial sp., No. (%)      
   S. sanguis 165 (55.74) 173 (56.91) 193 (63.91) 182 (59.87) 0.1758 
   P. intermedia 126 (42.57) 111 (36.51) 132 (43.71) 146 (48.03) 0.0383 
   T. forsythensis 81 (27.36) 98 (32.24) 127 (42.05) 147 (48.36) <.0001 
   Capnocytophaga sp. 108 (36.49) 97 (31.91) 127 (42.05) 118 (38.82) 0.0695 
   E. saburreum 81 (27.36) 82 (26.97) 112 (37.09) 121 (39.80) 0.0005 
   C. rectus  41 (13.85) 42 (13.82) 53 (17.55) 66 (21.71) 0.0272 
   P. gingivalis 32 (10.81) 33 (10.86) 43 (14.24) 67 (22.04) 0.0001 
   F. nucleatum 35 (11.82) 39 (12.83) 43 (14.24) 51 (16.78) 0.3234 
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Table 4.7 Population categorical characteristics for WHI OsteoPerio ancillary 
study participants by severity of Group 1 bacterial infection  
 
 Group 1 Bacterial Infection 
 
None/mild 
(n=322) 
Moderate 
(n=688) 
Severe 
(n=196) 
P value 
Age at enrollment     
   <70 years 575 (67.65) 181 (65.11) 46 (58.97) 
0.2558 
   ≥70 years 275 (32.35) 97 (34.89) 32 (41.03) 
Total family 
income 
    
   <$50,000 519 (61.06) 184 (66.19) 53 (67.95) 
0.1880 
   ≥$50,000 331 (38.94) 94 (33.81) 25 (32.05) 
Education     
   High School 172 (20.57) 57 (20.88) 20 (26.32) 
0.1991    College 363 (43.42) 136 (49.82) 31 (40.79) 
   Post-College 301 (36.00) 80 (29.30) 25 (32.89) 
BMI     
   Underweight/ 
   Normal 
   (< 24.9 kg/m2) 
406 (47.76) 110 (39.57) 25 (32.05) 
0.0148    Overweight  
   (25.0- 29.9 kg/m2) 
273 (32.12) 102 (36.69) 36 (46.15) 
   Obese  
   (≥30.0 kg/m2) 171 (20.12) 66 (23.74) 17 (21.79) 
Cigarette smoking     
   Never 471 (55.41) 124 (44.60) 40 (51.28) 
0.0365    Former 353 (41.53) 142 (51.08) 36 (46.15) 
   Current 26 (3.06) 12 (4.32) 2 (2.56) 
Birth control 
usage 
331 (38.94) 102 (36.69) 23 (29.49) 0.2336 
Cardiac 
therapeutic usage 
17 (2.00) 9 (3.26) 3 (3.85) 0.3458 
Mean CAL     
   Q1 231 (27.18) 54 (19.42) 11 (14.10) 
<.0001 
   Q2 234 (27.53) 56 (20.14) 14 (17.95) 
   Q3 201 (23.65) 82 (29.50) 19 (24.36) 
   Q4 184 (21.65) 86 (30.94) 34 (43.59) 
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Table 4.8 Population continuous characteristics for WHI OsteoPerio ancillary 
study participants by severity of Group 1 bacterial infection  
 
 Group 1 Bacterial Infection 
 
None/mild 
(n=322) 
Moderate 
(n=688) 
Severe  
(n=196) 
P value 
Age at 
enrollment, 
mean±SD, y 
66.26±7.04 66.47±6.81 68.85±6.17 0.069 
Physical 
activity, 
mean±SD, 
MET hours 
per week 
14.74±14.36 14.08±14.28 12.46±13.83 0.3701 
Diastolic BP, 
mean±SD, 
mmHg 
70.76±9.02 70.79±8.81 71.04±8.85 0.9668 
Caffeine 
intake, 
mean±SD, 
dietary 
caffeine mg 
162.97±122.44 172.86±129.40 202.32±163.58 0.0265 
Alcohol 
intake, 
mean±SD, 
servings per 
week 
2.59±4.51 2.96±5.52 2.78±4.19 0.5246 
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Table 4.9 Population categorical characteristics for WHI OsteoPerio ancillary 
study participants by severity of Group 2 bacterial infection  
 
 Group 2 Bacteria 
 0  
(n=610) 
1  
(n=346) 
2  
(n=250) 
P value 
Age at enrollment     
   <70 years 411 (67.38) 221 (63.87) 170 (68.00) 
0.4641 
   ≥70 years 199 (32.62) 125 (36.13) 80 (32.00) 
Total family income     
   <$50,000 383 (62.79) 213 (61.56) 160 (64.00) 
0.8292 
   ≥$50,000 227 (37.21) 133 (38.44) 90 (36.00) 
Education     
   High School 129 (21.68) 75 (21.87) 45 (18.22) 
0.4114    College 264 (44.37) 160 (46.65) 106 (42.91) 
   Post-College 202 (33.95) 108 (31.49) 96 (38.87) 
BMI     
   Underweight/ 
   Normal 
   (< 24.9 kg/m2) 
295 (48.36) 148 (42.77) 98 (39.20) 
0.0185    Overweight  
   (25.0- 29.9 kg/m2) 
185 (30.33) 121 (34.97) 105 (42.00) 
   Obese  
   (≥30.0 kg/m2) 130 (21.31) 77 (22.25) 47 (18.80) 
Cigarette smoking     
   Never 319 (52.30) 180 (52.02) 136 (54.40) 
0.6121    Former 266 (43.61) 157 (45.38) 108 (43.20) 
   Current 25 (4.10) 9 (2.60) 6 (2.40) 
Birth control usage 237 (38.85) 125 (36.13) 94 (37.60) 0.7035 
Cardiac therapeutic 
usage 
12 (1.98) 10 (2.90) 7 (2.80) 0.6081 
Mean CAL     
   Q1 160 (26.23) 83 (23.99) 53 (21.20) 
0.0047 
   Q2 171 (28.03) 87 (25.14) 46 (18.40) 
   Q3 143 (23.44) 79 (22.83) 80 (32.00) 
   Q4 136 (22.30) 97 (28.03) 71 (28.40) 
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Table 4.10 Population continuous characteristics for WHI OsteoPerio ancillary 
study participants by severity of Group 2 bacterial infection  
 
 Group 2 Bacteria 
 0  
(n=610) 
1  
(n=346) 
2  
(n=250) 
P value 
Age at enrollment, 
mean±SD, y 66.39±6.94 66.60±7.09 66.50±6.84 0.8975 
Physical activity, 
mean±SD, MET hours 
per week 
14.73±14.5
9 
13.97±13.83 14.40±14.32 0.7372 
Diastolic BP, 
mean±SD, mmHg 70.79±8.71 70.92±9.06 70.57±9.42 0.8922 
Caffeine intake, 
mean±SD, dietary 
caffeine mg 
167.33±125
.68 
160.68±118.8
4 
179.12±142.
10 
0.2255 
Alcohol intake, 
mean±SD, servings 
per week 
2.74±5.10 2.33±3.87 3.07±4.95 0.1674 
 
 Table 4.11 Unadjusted and adjusted odds of suffering from migraines by exposure status for WHI OsteoPerio 
ancillary study participants 
 
 Crude OR (95% CI ) P value Adjusted OR (95% CI)a P value 
CDC/AAP Definition of Periodontal Diseaseb 
Severe/Moderate Periodontal Disease  0.812 (0.544, 1.213) 0.3097 0.811 (0.530, 1.241) 0.3343 
Mean CALc 
Mean CAL Q2 1.109 (0.673, 1.827) 0.6850 1.071 (0.628, 1.828) 0.8012 
Mean CAL Q3 1.746 (1.000, 3.048) 0.0500 1.638 (0.904, 2.966) 0.1038 
Mean CAL Q4 1.065 (0.648, 1.749) 0.8035 0.930 (0.546, 1.584) 0.7900 
Infection with Group 1 Bacteriad 
Moderate Infection 1.622 (0.992, 2.652) 0.0540 1.565 (0.922, 2.658) 0.0973 
Severe Infection 1.589 (0.673, 3.754) 0.2907 1.385 (0.547, 3.505) 0.4922 
   S. sanguis 0.904 (0.620, 1.320) 0.6025 0.927 (0.623, 1.379) 0.7073 
   P. intermedia 0.960 (0.662, 1.392) 0.8304 0.972 (0.656, 1.439) 0.8856 
   T. forsythensis 1.414 (0.950, 2.102) 0.0874 1.337 (0.720, 2.481) 0.3579 
   C. rectus  0.963 (0.592, 1.567) 0.8791 0.968 (0.583, 1.605) 0.8982 
   P. gingivalis 2.109 (1.082, 4.110) 0.0283 2.252 (1.121, 4.526) 0.0226 
   F. nucleatum 1.466 (0.806, 2.669) 0.2104 1.337 (0.720, 2.481) 0.3579 
Infection with Group 2 Bacteriae 
Infection with 1 Group 2 Bacteria 0.821 (0.545, 1.236) 0.3447 0.776 (0.498, 1.207) 0.2599 
Infection with 2 Group 2 Bacteria 1.455 (0.852, 2.484) 0.1699 1.363 (0.756, 2.458) 0.3036 
   Capnocytophaga sp. 1.115 (0.759, 1.637) 0.5803 1.159 (0.773, 1.738) 0.4758 
   E. saburreum 1.230 (0.822, 1.842) 0.3145 1.303 (0.853, 1.989) 0.2205 
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac 
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild 
periodontal disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection;  
e Reference group: 0 Group 2 bacteria present 
4
1
 
  
Table 4.12 Unadjusted and adjusted odds of suffering from mild headache symptoms by exposure status for WHI 
OsteoPerio ancillary study participants 
 
 Crude OR (95% CI) P value Adjusted OR* (95% CI) P value 
CDC/AAP Definition of Periodontal Diseaseb 
Severe/Moderate Periodontal Disease  0.865 (0.699, 1.119) 0.2698 0.758 (0.336, 1.710) 0.5039 
Mean CALc 
Mean CAL Q2 1.015 (0.735, 1.402) 0.9288 0.986 (0.701, 1.387 0.9349 
Mean CAL Q3 0.980 (0.708, 1.356) 0.9036 1.040 (0.737, 1.467) 0.8248 
Mean CAL Q4 0.818 (0.591, 1.131) 0.2239 0.838 (0.593, 1.185) 0.3186 
Infection with Group 1 Bacteriad 
Moderate Infection 0.855 (0.649,1.125) 0.2642 0.844 (0.623,1.144) 0.2751 
Severe Infection 0.801 (0.499,1.287) 0.3591 0.855 (0.527,1.488) 0.6448 
   S. sanguis 1.124 (0.891,1.418) 0.3251 1.104 (0.864,1.410) 0.4282 
   P. intermedia 0.848 (0.673,1.069) 0.1631 0.831 (0.650,1.061) 0.1380 
   T. forsythensis 0.915 (0.723,1.158) 0.4606 0.993 (0.772,1.277) 0.9566 
   C. rectus  0.867 (0.638,1.178) 0.3614 0.814 (0.590,1.122) 0.7975 
   P. gingivalis 0.791 (0.570,1.096) 0.1591 0.850 (0.602,1.198) 0.3527 
   F. nucleatum 0.913 (0.656,1.272) 0.5921 1.028 (0.723,1.463) 0.8758 
Infection with Group 2 Bacteriae 
Infection with 1 Group 2 Bacteria 0.986 (0.755,1.287) 0.9161 1.016 (0.764,1.352) 0.9109 
Infection with 2 Group 2 Bacteria 0.902 (0.670,1.215) 0.4983 0.973 (0.695,1.363) 0.8752 
   Capnocytophaga sp. 0.902 (0.712,1.142) 0.3908 0.907 (0.708,1.163) 0.4426 
   E. saburreum 0.979 (0.768,1.248) 0.8628 0.977 (0.756,1.261) 0.8569 
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac 
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal 
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference 
group: 0 Group 2 bacteria present 
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 Table 4.13 Unadjusted and adjusted odds of suffering from moderate headache symptoms by exposure status for 
WHI OsteoPerio ancillary study participants 
 
 Crude OR (95% CI) P value Adjusted OR* (95% CI) P value 
CDC/AAP Definition of Periodontal Diseaseb 
Severe/Moderate Periodontal Disease  0.737 (0.497,1 .091) 0.1276 0.728 (0.483, 1.098) 0.1299 
Mean CALc 
Mean CAL Q2 0.699 (0.402, 1.112) 0.1207 0.614 (0.356, 1.059) 0.0797 
Mean CAL Q3 0.687 (0.413, 1.141) 0.1471 0.728 (0.427, 1.239) 0.2417 
Mean CAL Q4 0.726 (0.440, 1.196) 0.2085 0.806 (0.479, 1.355) 0.4148 
Infection with Group 1 Bacteriad 
Moderate Infection 0.875 (0.561, 1.366) 0.5579 0.819 (0.507, 1.322) 0.4138 
Severe Infection 0.422 (0.151, 1.181) 0.1004 0.458 (0.161, 1.306) 0.1442 
   S. sanguis 1.138 (0.781, 1.657) 0.5018 1.092 (0.739, 1.615) 0.6589 
   P. intermedia 0.907 (0.625, 1.316) 0.6072 0.845 (0.571, 1.251) 0.4008 
   T. forsythensis 0.747 (0.506, 1.105) 0.1441 0.817 (0.543, 1.231) 0.3344 
   C. rectus  0.837 (0.501, 1.397) 0.4957 0.751 (0.436, 1.293) 0.3019 
   P. gingivalis 0.694 (0.389, 1.240) 0.2171 0.764 (0.424, 1.380) 0.3725 
   F. nucleatum 1.006 (0.594, 1.706) 0.9814 1.114 (0.643, 1.928) 0.7007 
Infection with Group 2 Bacteriae 
Infection with 1 Group 2 Bacteria 1.672 (1.111, 2.516) 0.0137 1.753 (1.139, 2.697) 0.0108 
Infection with 2 Group 2 Bacteria 1.051 (0.635, 1.740) 0.8473 1.168 (0.683, 1.998) 0.5697 
   Capnocytophaga sp. 1.217 (0.840, 1.765) 0.2997 1.229 (0.833, 3.409) 0.2986 
   E. saburreum 1.052 (0.715, 1.547) 0.7980 1.090 (0.730, 1.628) 0.6732 
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac 
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal 
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference 
group: 0 Group 2 bacteria present 
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Table 4.14 Unadjusted and adjusted odds of suffering from severe headache symptoms by exposure status for WHI 
OsteoPerio ancillary study participants 
 
 Crude OR (95% CI) P value Adjusted OR* (95% CI) P value 
CDC/AAP Definition of Periodontal Diseaseb 
Severe/Moderate Periodontal Disease  0.768 (0.358,1.650) 0.4988 0.758 (0.336,1.710) 0.5039 
Mean CALc 
Mean CAL Q2 0.518 (0.189,1.419) 0.2005 0.510 (0.168,1.544) 0.2334 
Mean CAL Q3 0.687 (0.413,1.141) 0.1471 0.535 (0.176,1.622) 0.2688 
Mean CAL Q4 0.700 (0.277,1.765) 0.4494 0.858 (0.325,2.265) 0.3186 
Infection with Group 1 Bacteriad 
Moderate Infection 0.608 (0.231,1.605) 0.3152 0.726 (0.269,1.956) 0.5265 
Severe Infection 0.431 (0.058,3.229) 0.4131 0.530 (0.070,4.024) 0.5389 
   S. sanguis 0.727 (0.356,1.484) 0.3810 0.641 (0.298,1.380) 0.2559 
   P. intermedia 0.741 (0.352,1.560) 0.4299 0.783 (0.354,1.730) 0.5451 
   T. forsythensis 0.670 (0.306,1.468) 0.3170 0.871 (0.387,1.964) 0.7399 
   C. rectus  1.190 (0.482,2.940) 0.7061 1.361 (0.540,3.427) 0.5135 
   P. gingivalis 0.626 (0.188,2.083) 0.4454 0.745 (0.221,2.512) 0.6353 
   F. nucleatum 0.917 (0.317,2.654) 0.8726 1.152 (0.392,3.385) 0.7975 
Infection with Group 2 Bacteriae 
Infection with 1 Group 2 Bacteria 2.856 (1.281,6.368) 0.0103 3.169 (1.310,7.663) 0.0105 
Infection with 2 Group 2 Bacteria 1.202 (0.407,3.555) 0.7388 1.578 (0.507,4.910) 0.4312 
   Capnocytophaga sp. 1.570 (0.768,3.207) 0.2161 1.583 (0.735,3.409) 0.2403 
   E. saburreum 1.114 (0.529,2.350) 0.7758 1.337 (0.613,2.918) 0.4659 
a Adjusting for age, education, income, BMI, smoking status, physical activity, history of birth control or cardiac 
therapeutic usage, blood pressure, and alcohol and caffeine consumption; b Reference group: No or mild periodontal 
disease; c Reference group: Mean CAL Q1; d Reference group: No or mild Group 1 bacterial infection; e Reference 
group: 0 Group 2 bacteria present 
4
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CHAPTER 5 
CONCLUSIONS 
 
5.1 Discussion: 
5.1.1 Migraines 
 Periodontal disease, as defined by the CDC/AAP and by quartiles of mean 
CAL, was not significantly associated with migraines among older, predominantly 
white women in the US. The Fifth European Workshop on Periodontology, 
hosted in 2005, used CAL as the sole marker of periodontitis in epidemiologic 
studies of risk factors. In 2007, the CDC/AAP proposed the first draft of the 
rankings used to address the first hypothesis of Aim 1. The current rankings 
included cases definitions for three instead of two rankings. Since then, the 
rankings set by the CDC/AAP have been used in numerous epidemiological 
studies (Page & Eke, 2007; Penoni, Torres, Farias, & Fernandes, 2016) and it 
has even been suggested that these rankings could be standardized for all future 
population-based studies of periodontal disease (Page & Eke, 2007).   
 However, these definitions are based on measurements of periodontal 
destruction (PD and CAL), which capture the damage caused by inflammation 
and are not indicative of a current inflammatory response. Furthermore, both PD 
and CAL may lead to misclassification as using PD might result in pseudo-pocket 
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to be considered true and using CAL may similarly cause sites of gingival 
recession by mechanical forces to be considered true symptoms of periodontal 
disease (Pei, He, & Ouyang, 2012). Because we are suggesting that the 
inflammatory responses related to a current periodontal infection are related to 
migraines, the association would likely be underestimated by these exposure 
measures as they can lead to an overestimation of periodontal disease presence. 
Conversely, using PD and CAL as measures of periodontal disease can also 
lead to an underestimation of periodontal disease prevalence, as both measures 
only consider the interproximal sites of teeth and periodontal disease can also 
occur at buccal and lingual sites. To combat these issues, Pei and colleagues 
proposed a three-level definition of periodontal disease that uses PD, CAL, and 
additionally measure, bleeding on probing (BOP), to define the severity of 
disease where all six sites per tooth were considered (Pei et al., 2012). A positive 
BOP would be indicative of a current infection and its subsequent inflammatory 
responses. Future investigations into the relationship between periodontal 
disease and migraines would benefit from using this definition of periodontal 
disease. Because of this potential misclassification bias, our study may have 
failed to detect meaningful differences between those with and without 
periodontal disease. Future investigations into the relationship between 
periodontal disease and migraines should consider a more inclusive definition 
that accounts for inflammation.  
 Peskersoy and colleagues reported findings from their investigation into 
the relationship between migraines and oral comorbidities. They found that 
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participants with migraines reported more frequently tooth wear and abrasion. 
Furthermore, they found that two additional measures of oral health, DMFT and 
plaque index scores were significantly associated with migraines. While this is 
evidence of a relationship between oral health and migraines, this study did not 
use any of the measures or definitions of periodontal disease used in this study, 
making comparisons between their study and ours impossible. 
 Participants with Group 1 bacteria present reported migraine more 
frequently (Moderate infection adjusted OR = 1.565, 95% CI: 0.922, 2.658; 
severe infection adjusted OR = 1.385, 95% CI: 0.547, 3.505), even though this 
did not reach statistical significance.  However, the presence of P. gingivalis was 
positively associated with migraines (adjusted OR = 2.252, 95% CI: 1.121, 
4.526). As a prominent member of the oral microbiome and the demonstrated 
ability to colonize the oral epithelial, P. gingivalis is considered a keystone 
species in periodontal disease as a member of the “red complex” identified by 
Haffajee and colleagues, which has been strongly implicated in periodontal 
disease (Haffajee, Socransky, Patel, & Song, 2008). As part of the immune 
response to periodontal disease, the immune system produces the antimicrobial 
agent, NO. The lipid A-associated proteins of the P. gingivalis LPS (PgLPS) has 
been shown to induce nitric oxide production in clinical studies (E. Y. Choi et al., 
2007; Herath et al., 2016) and is considered a crucial virulence factor in 
periodontal pathogenesis. Our study provides evidence of a significant, positive 
association between a bacterial species, P. gingivalis, and migraines. 
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Gonzalez and colleagues, in a collaboration with Knight labs, were the first 
to suggest a relationship between oral bacteria and migraines (Gonzalez et al., 
2016). They reported significant increases in nitrate, nitrite, and nitric oxide 
reductase genes in oral samples collected from those who suffer from migraines. 
After claiming they had evidence of a potential link between oral microbes and 
migraines, the results of this study were sensationalized by numerous national 
news sources. A criticism of this study was that the authors implied that they 
directly measured genes of interests related to reducing nitrates and nitrites. 
However, their predictions were based on prior projects, and did not directly 
demonstrate link between periodontal bacteria, nitric oxide production, and 
migraines. Additionally, none of their methods or results suggested any 
consideration for important confounders. Infection with Group 2 bacteria was not 
associated with migraines.  
5.1.2 Headache Disorders 
 Periodontal disease, defined two ways, was not associated with headache 
disorders. Furthermore, headaches were not related to the presence of Group 1 
bacteria. We hypothesized that the presence of NO producing oral bacteria 
(Group 1) would be positively associated with migraines. As headaches have 
many different causes, the association of Group 1 bacteria and headaches would 
not have expected to be strong. Without differentiating the type of headache 
disorder, it is impossible to limit our exposure population to only those headache 
disorders linking to NO.  
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 Contradictory to our second hypothesis of Aim 2, Group 2 bacteria were 
positively associated with headache disorders. Infection with a Group 2 
bacterium was significantly associated with moderate and severe headache 
symptoms (Moderate symptom adjusted OR = 1.753; 95% CI: 1.139,2.697; 
Severe symptom adjusted OR = 3.169, 95% CI: 1.310,7.663); however, no 
individual species of Group 2 bacteria was associated with migraines.  
As periodontal disease and its associated bacterial pathogens have been 
shown to induce NO production by the immune system (Eun Young Choi et al., 
2011; Kim, Ha, Choi, Choi, & Choi, 2004; Pelt, Zimmermann, Ulbrich, & 
Bernimoulin, 2002; Skaleric, Gaspirc, McCartney-Francis, Masera, & Wahl, 2006; 
Hussain, Mckay, Gonzales-Marin, & Allaker, 2015; E. Y. Choi et al., 2007; Herath 
et al., 2016; Kato, Mikami, & Saito, 2001; Velsko et al., 2015; Chukkapalli et al., 
2015; English, Patrick, Orlicek, McCordic, & Shenep, 1996; Jian Jun Gao, Xue, 
Zuvanich, Haghi, & Morrison, 2001; Kendall, Haase, Li, Xiao, & Bartold, 2000; 
Hirose et al. 2001), and NO has been implicated in the pathophysiology of 
headache disorders (D’andrea et al., 1994; Gruber et al., 2010; Olesen, 2008; 
Sarchielli et al., 1996; Shimomura et al., 1999), it is biologically feasible that 
periodontal disease and its associated bacterial pathogens to be positively 
associated with headache disorders.  
Additionally, it is important to note, that estrogen has been shown to be 
protective against periodontal disease (Brasil et al., 2017; Nebel, 2012), but is 
associated with headache disorders, and migraines in particular (Chai, Peterlin, 
& Calhoun, 2014). Estrogen plays an important role in regulating inflammatory 
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responses to infection, specifically the production of NO (Brasil et al., 2017; 
Nevzati et al., 2015; Townsend, Meuchel, Thompson, Pabelick, & Prakash, 
2011). Estrogen receptors (ER), ERα and ERβ are expressed in smooth muscle 
cells, macrophages, and endothelial cells, and activation of ERα in endothelial 
cells has shown to increase the expression of NO synthase (eNOS) in the 
presence of estrogen (17β-estradiol) (Furchgott, 1999; Mendelsohn, 2000; Chen 
et al., 1999). Furthermore, mutations in the ERα gene have been associated with 
increased risk of periodontal disease (Weng et al., 2015). The ability of ERs to 
increase NO production in the presence of estrogen could explain the increased 
prevalence of headache disorders in women (Chai et al., 2014) 
 Findings from our investigation into the relationship between periodontal 
disease and the subsequent production of NO due to its related pathogenic 
bacteria and headache disorders provides some evidence of the association 
between our exposures of interest and migraines but not between our general 
headache disorder variable. Further investigations into the periodontal disease 
and headache disorders is warranted. 
5.2 Strengths: 
This study has several strengths. First, the WHI ancillary OsteoPerio study 
had information on all important, potential confounders in the relationship 
between periodontal disease and its ensuing inflammatory responses and 
headache disorders. This allowed for statistical control of potential confounders. 
Second, the variables from the OsteoPerio study were carefully chosen, 
collected, and measured. Third, a biologically plausible hypothesis linking NO 
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producing oral bacteria and migraines was tested. Lastly, my study these findings 
contribute to an understudied area on headache etiology.  
5.3 Limitations:  
First, self-reported headache is vulnerable to misclassification bias.  A 
recent validation study found high concordance between self-reported 
questionnaire data and medical records (κ=.61 for chronic conditions), 
suggesting our study would only minimally be influenced by misclassification bias 
(Van Gelder et al., 2015). Second, the bacterial species were classified as 
present or absent with no quantification limiting the statistical analyses at our 
disposal. Third, the results of our study are not generalizable to the entire United 
States population, but to older women aged 53 to 83. These results need to be 
replicated in other populations.  
Last, this study used a cross-sectional design and therefore temporality 
cannot be assessed. This is particularly problematic since headache disorders 
are more prevalent amongst younger individuals (Younger, 2016), and 
conversely periodontal disease, as defined by periodontal destruction, is typically 
more prevalent in older populations and includes past and current infection 
(Leite, Peres, Do, Demarco, & Peres, 2017; Page & Eke, 2007). However, the 
proposed biological plausibility explains this perceived paradox. NO produced by 
the immune system in response periodontal disease causes the vasodilation 
responsible for the pain suffered from headache disorders. It is well established 
that the immune system declines with age, including the production of NO 
(Kissin, Tomasi, McCartney-Francis, Gibbs, & Smith, 1997; Liang, Domon, 
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Hosur, Wang, & Hajishengallis, 2009). If our hypotheses are correct, the aging 
body’s declining ability to illicit an immune response, specifically the production of 
NO, not only explains the body’s decreased ability to fight the infections 
associated with periodontal disease, but also explains the decrease headache 
disorder prevalence in older populations. Furthermore, results from the National 
Health and Nutrition Examination Survey (NHANES) 2009-2012 suggests that 
almost half of adults age 30 years and older have periodontal disease with 
severe periodontal disease affecting 8.9% of the population (Eke et al., 2015). 
Moreover, NHANES III data suggest 90% of persons aged 20-79 needed 
periodontal treatment with increasing complexity of periodontal treatments with 
age (Dye & Vargas, 2002). While periodontal disease is associated with older 
age, children and adolescence also suffer (Merchant et al., 2015). 
5.4 Importance:  
Headaches are the 6th leading cause of disability globally. Approximately 
46% of the adult population suffers from headaches, 42% suffer from tension-
type headaches, 11% suffer from migraines, and 3% suffer from chronic daily 
headaches (Stovner et al., 2007). Considering the disability induced by headache 
disorders, further investigation into their cause is warranted. The literature on the 
association between periodontal disease and headache disorders is limited, even 
though it is biologically plausible. Our study provides epidemiological data on the 
association between periodontal disease and headache disorders.  
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5.5 Conclusions: 
 P. gingivalis presence is positively associated with migraines among older 
white women after controlling for potential confounders. Further investigation into 
measures of oral health, oral microbes, and NO in relation to headache disorders 
is warranted.  
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